In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Edwards Lifesciences trades above its fair value of $73.32, indicating potential overvaluation with a -15.4% downside implied. Valuation methods, especially DCF and P/E, show moderate downside risk, while its high liquidity and leverage contrast with low growth (1/5). Monte Carlo reveals substantial volatility and downside risk (83.3% scenarios below current price).